Elizabeth Balta

Elizabeth Balta is the General Counsel and Corporate Secretary of Jade Biosciences. She most recently served as General Counsel of Icosavax, where she led all aspects of the company’s legal affairs from September 2021 until the acquisition of Icosavax by AstraZeneca in February 2024. Prior to joining Icosavax, Ms. Balta served as Associate General Counsel at Seagen Inc. from March 2016 to September 2021 where she helped lead and build the legal affairs group as Seagen transformed into a global, multi-product company.

Previously, she oversaw the legal function at Oncothyreon, Inc. where she handled a wide range of corporate, securities, clinical, manufacturing, licensing and transactional matters from 2012 to 2016. Prior to Oncothyreon, Ms. Balta served in roles of increasing responsibility at Emergent BioSolutions Inc. and Trubion Pharmaceuticals, Inc. from 2009 to 2012. Ms. Balta began her legal career as a corporate associate at Fenwick & West LLP and Orrick, Herrington Sutcliffe LLP where she advised early stage and public biopharmaceutical companies.

Ms. Balta received her J.D. from Harvard Law School and a B.A. in Human Biology from Stanford University.